T1	PROC 44 64	Estudio de extensión
T2	PROC 70 90	evaluar la seguridad
#1	AnnotatorNotes T2	C1705187; Safety Study; Research Activity
T3	DISO 122 141	síndrome de Cushing
#2	AnnotatorNotes T3	C0010481; Cushing Syndrome; Disease or Syndrome
T4	CHEM 195 207	osilodrostat
#3	AnnotatorNotes T4	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T5	PROC 255 299	Estudio de extensión, multicéntrico, abierto
T6	PROC 305 325	evaluar la seguridad
#4	AnnotatorNotes T6	C1705187; Safety Study; Research Activity
T7	DISO 357 376	síndrome de Cushing
#5	AnnotatorNotes T7	C0010481; Cushing Syndrome; Disease or Syndrome
T8	CHEM 430 442	osilodrostat
#6	AnnotatorNotes T8	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T9	PROC 539 561	tratamiento continuado
T10	DISO 601 620	Síndrome de Cushing
#7	AnnotatorNotes T10	C0010481; Cushing Syndrome; Disease or Syndrome
T11	CHEM 444 450	LCI699
#8	AnnotatorNotes T11	C2976005; LCI699 Organic Chemical; Pharmacologic Substance
T12	CHEM 566 578	osilodrostat
#9	AnnotatorNotes T12	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T13	PROC 924 935	tratamiento
#10	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 1057 1066	protocolo
#11	AnnotatorNotes T14	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T15	CHEM 760 772	osilodrostat
#12	AnnotatorNotes T15	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T16	CHEM 940 952	osilodrostat
#13	AnnotatorNotes T16	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T17	PROC 1347 1367	estudio de extension
T18	PROC 1418 1431;1452 1466	discontinuado el tratamiento
#14	AnnotatorNotes T18	C0850893; stop medication; Therapeutic or Preventive Procedure
T19	PROC 1237 1261;1293 1300	consentimiento informado escrito
#15	AnnotatorNotes T19	C0811741; Obtain informed written consent; Health Care Activity
T20	CHEM 1576 1588	osilodrostat
#16	AnnotatorNotes T20	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T21	PROC 1608 1620;1636 1650	tratamientos experimentales
#17	AnnotatorNotes T21	C0949266; Therapies, Investigational; Therapeutic or Preventive Procedure
T22	PROC 1786 1809	métodos anticonceptivos
#18	AnnotatorNotes T22	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T23	CHEM 1911 1921	medicación
#19	AnnotatorNotes T23	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T24	PROC 1218 1229	tratamiento
#20	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	CHEM 1479 1491	osilodrostat
#21	AnnotatorNotes T25	C4330903; osilodrostat; Organic Chemical · Pharmacologic Substance
T26	PROC 1841 1855	administración
#22	AnnotatorNotes T26	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T27	DISO 796 798	SC
#23	AnnotatorNotes T27	C0010481; Cushing Syndrome; Disease or Syndrome
T28	DISO 1673 1675	SC
#24	AnnotatorNotes T28	C0010481; Cushing Syndrome; Disease or Syndrome
T29	PROC 1898 1921	suspender la medicación
#25	AnnotatorNotes T29	C0850893; stop medication; Therapeutic or Preventive Procedure
T30	Date 12 16	2017
T31	Date 91 104	a largo plazo
T32	LIVB 108 117	pacientes
#26	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T33	Date 326 339	a largo plazo
T34	LIVB 343 352	pacientes
#27	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	LIVB 486 498	investigador
#28	AnnotatorNotes T35	C0035173; Research Personnel; Professional or Occupational Group
T36	LIVB 650 659	Pacientes
#29	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	Date 683 694	actualmente
T39	LIVB 873 882	Pacientes
#30	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	Date 908 919	actualmente
T41	LIVB 982 994	investigador
#31	AnnotatorNotes T41	C0035173; Research Personnel; Professional or Occupational Group
T42	LIVB 999 1008	Pacientes
#32	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	LIVB 1114 1126	investigador
#33	AnnotatorNotes T43	C0035173; Research Personnel; Professional or Occupational Group
T44	LIVB 1131 1140	Pacientes
#34	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T46	LIVB 1398 1407	Pacientes
#35	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	LIVB 1545 1554	Pacientes
#36	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T50	LIVB 1688 1733	Mujeres embarazadas o en periodo de lactancia
#37	AnnotatorNotes T50	C0033011; Pregnant Women; Population Group | C4316174; Patients who are breastfeeding; Patient or Disabled Group
T51	LIVB 1737 1759	Mujeres en edad fértil
#38	AnnotatorNotes T51	C4324275; Woman of childbearing potential; Population Group
T52	Age 1748 1759	edad fértil
T53	PHYS 1724 1733	lactancia
#39	AnnotatorNotes T53	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T55	Duration 1878 1886	1 semana
T56	LIVB 1280 1292	adolescentes
#40	AnnotatorNotes T56	C0205653; Adolescent (age group); Age Group
T38	PHYS 1696 1707	embarazadas
#41	AnnotatorNotes T38	C0032961; Pregnancy; Organism Function
T45	PROC 1174 1181	visitas
#42	AnnotatorNotes T45	C1512346; Patient Visit; Health Care Activity
A1	Population_data T56 Age
A2	Population_data T51 Age
A4	Status T4 History_of
A7	Status T8 History_of
A8	Status T11 History_of
A5	Status T23 History_of
A6	Status T25 History_of
#43	AnnotatorNotes T31	C0443252; Long-term; Temporal Concept
#44	AnnotatorNotes T33	C0443252; Long-term; Temporal Concept
#45	AnnotatorNotes T37	C0521116; Current (present time); Temporal Concept 
#46	AnnotatorNotes T40	C0521116; Current (present time); Temporal Concept 
T48	Neg_cue 1621 1623	no
T49	Quantifier_or_Qualifier 1624 1633	aprobados
A3	Assertion T49 Negated
R1	Overlap Arg1:T2 Arg2:T31	
R2	Experiences Arg1:T32 Arg2:T3	
R3	Experiences Arg1:T32 Arg2:T4	
T54	Quantifier_or_Qualifier 142 150	endógeno
#47	AnnotatorNotes T54	C0205227; Endogenous; Functional Concept
R4	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T54	
R5	Overlap Arg1:T6 Arg2:T33	
R6	Experiences Arg1:T34 Arg2:T7	
T57	Quantifier_or_Qualifier 377 385	endógeno
#48	AnnotatorNotes T57	C0205227; Endogenous; Functional Concept
R7	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T57	
R8	Experiences Arg1:T34 Arg2:T8	
R9	Experiences Arg1:T34 Arg2:T11	
R10	Used_for Arg1:T12 Arg2:T9	
R11	Experiences Arg1:T34 Arg2:T9	
T58	Observation 522 534	beneficiando
R12	Experiences Arg1:T34 Arg2:T58	
R13	Causes Arg1:T9 Arg2:T58	
T59	Observation 670 682;695 708	participando en un estudio
#49	AnnotatorNotes T59	C1278516; Patient participation status; Finding
R14	Overlap Arg1:T59 Arg2:T37	
R15	Experiences Arg1:T36 Arg2:T15	
R16	Overlap Arg1:T59 Arg2:T15	
R17	Experiences Arg1:T36 Arg2:T27	
T60	Quantifier_or_Qualifier 799 807	endógeno
#50	AnnotatorNotes T60	C0205227; Endogenous; Functional Concept
R18	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T60	
T61	Observation 818 846	cumplido todos los criterios
#51	AnnotatorNotes T61	C4329786; Eligibility Criteria Met By Subject; Finding
T62	Observation 893 907	beneficiándose
R19	Experiences Arg1:T39 Arg2:T62	
R20	Overlap Arg1:T62 Arg2:T40	
R21	Experiences Arg1:T39 Arg2:T13	
R22	Used_for Arg1:T16 Arg2:T13	
T63	Observation 1030 1066	cumplir los requisitos del protocolo
#52	AnnotatorNotes T63	C0582783; Ability to comply with treatment; Finding (?)
T64	Observation 1145 1151	deseen
#53	AnnotatorNotes T64	C0600109; Willing; Finding
T65	Observation 1154 1229	puedan realizar las visitas programadas y cumplir los planes de tratamiento
T66	Observation 1262 1274	asentimiento
#54	AnnotatorNotes T66	C1302239; Patient consented to clinical trial; Finding (?)
R23	Before Arg1:T19 Arg2:T17	
R24	Before Arg1:T66 Arg2:T17	
R25	Experiences Arg1:T46 Arg2:T18	
R26	Used_for Arg1:T25 Arg2:T18	
R27	Experiences Arg1:T47 Arg2:T20	
R28	Combined_with Arg1:T20 Arg2:T21	
R29	Negation Arg1:T48 Arg2:T49	
R30	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T49	
R31	Experiences Arg1:T47 Arg2:T28	
T67	Quantifier_or_Qualifier 1676 1684	endógeno
#55	AnnotatorNotes T67	C0205227; Endogenous; Functional Concept
R32	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T67	
R33	Experiences Arg1:T50 Arg2:T38	
R34	Experiences Arg1:T50 Arg2:T53	
R35	Has_Age Arg1:T51 Arg2:T52	
R36	Experiences Arg1:T51 Arg2:T22	
T68	Quantifier_or_Qualifier 1810 1829	altamente efectivos
R37	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T68	
R38	Overlap Arg1:T22 Arg2:T26	
R39	Has_Duration_or_Interval Arg1:T22 Arg2:T55	
R40	After Arg1:T22 Arg2:T29	
R41	Used_for Arg1:T23 Arg2:T29	
R42	Experiences Arg1:T51 Arg2:T26	
R43	Experiences Arg1:T51 Arg2:T29	
T69	CONC 1862 1867	dosis
#56	AnnotatorNotes T69	C0178602; Dosage; Quantitative Concept
R44	Used_for Arg1:T69 Arg2:T26	
R45	Overlap Arg1:T64 Arg2:T45	
R46	Overlap Arg1:T64 Arg2:T24	
#57	AnnotatorNotes T49	C0205540; Approved; Qualitative Concept
#58	AnnotatorNotes T1	C1709323; Open Label Study; Research Activity
#59	AnnotatorNotes T58	C4049461; Unexpected beneficial therapeutic response; Finding (?)
#60	AnnotatorNotes T62	C4049461; Unexpected beneficial therapeutic response; Finding (?)
A9	Assertion T22 Hypothetical
A10	Assertion T68 Hypothetical
A11	Experiencer T51 Patient
A12	Experiencer T50 Patient
A13	Experiencer T32 Patient
A14	Experiencer T34 Patient
A15	Experiencer T35 Other
A16	Experiencer T36 Patient
A17	Experiencer T39 Patient
A18	Experiencer T41 Other
A19	Experiencer T43 Other
A20	Experiencer T42 Patient
A21	Experiencer T44 Patient
A22	Experiencer T56 Patient
A23	Experiencer T46 Patient
A24	Experiencer T47 Patient
